JP2017535586A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535586A5 JP2017535586A5 JP2017528154A JP2017528154A JP2017535586A5 JP 2017535586 A5 JP2017535586 A5 JP 2017535586A5 JP 2017528154 A JP2017528154 A JP 2017528154A JP 2017528154 A JP2017528154 A JP 2017528154A JP 2017535586 A5 JP2017535586 A5 JP 2017535586A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- hydrogen
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 115
- 239000001257 hydrogen Substances 0.000 claims description 115
- 150000001875 compounds Chemical class 0.000 claims description 95
- 125000000217 alkyl group Chemical group 0.000 claims description 80
- 125000001072 heteroaryl group Chemical group 0.000 claims description 62
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims description 60
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 57
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 55
- 150000002431 hydrogen Chemical group 0.000 claims description 54
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 53
- 125000003118 aryl group Chemical group 0.000 claims description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical group 0.000 claims description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 210000003169 central nervous system Anatomy 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 239000002575 chemical warfare agent Substances 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 239000003691 GABA modulator Substances 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 3
- 208000009205 Tinnitus Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 206010048010 Withdrawal syndrome Diseases 0.000 claims description 3
- 208000029560 autism spectrum disease Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 230000036461 convulsion Effects 0.000 claims description 3
- 230000036407 pain Effects 0.000 claims description 3
- 208000022821 personality disease Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 208000020685 sleep-wake disease Diseases 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 201000009032 substance abuse Diseases 0.000 claims description 3
- 231100000736 substance abuse Toxicity 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 231100000886 tinnitus Toxicity 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 201000009916 Postpartum depression Diseases 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 235000020083 shōchū Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 description 40
- 0 C[C@@]1(CC[C@@](C)([C@@]2CC3)[C@]4(C)C3CC(C)(C)CC4)C(C(c(cccc3)c3F)=O)=*C[C@]12I Chemical compound C[C@@]1(CC[C@@](C)([C@@]2CC3)[C@]4(C)C3CC(C)(C)CC4)C(C(c(cccc3)c3F)=O)=*C[C@]12I 0.000 description 16
- 229910052799 carbon Inorganic materials 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 206010039897 Sedation Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 230000036280 sedation Effects 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- 208000009575 Angelman syndrome Diseases 0.000 description 2
- 208000001914 Fragile X syndrome Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000006289 Rett Syndrome Diseases 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000005809 status epilepticus Diseases 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- LKPVDGWWWXFWJJ-ROOJVTFQSA-N CC(CC1)(C(CC2)C(c(cc3)cc(C)c3F)O)[C@@H]2C(CC2)[C@H]1[C@@](C)(CC1)[C@@H]2C[C@]1(C)O Chemical compound CC(CC1)(C(CC2)C(c(cc3)cc(C)c3F)O)[C@@H]2C(CC2)[C@H]1[C@@](C)(CC1)[C@@H]2C[C@]1(C)O LKPVDGWWWXFWJJ-ROOJVTFQSA-N 0.000 description 1
- SKKKXWBZVMFJFJ-YSDXZOGCSA-N CC(CC1)([C@@H](CC2)C(CC3)[C@H]1C(C)(CC1)[C@@H]3C[C@]1(C)O)C2C(c1cc(C)c(C)cc1)=O Chemical compound CC(CC1)([C@@H](CC2)C(CC3)[C@H]1C(C)(CC1)[C@@H]3C[C@]1(C)O)C2C(c1cc(C)c(C)cc1)=O SKKKXWBZVMFJFJ-YSDXZOGCSA-N 0.000 description 1
- SEVLRZGBSQUYHK-PPGGWLFVSA-N CC(CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@](C)(CC1)C3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1OC(F)(F)F)=O Chemical compound CC(CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@](C)(CC1)C3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1OC(F)(F)F)=O SEVLRZGBSQUYHK-PPGGWLFVSA-N 0.000 description 1
- OYCAXWJZOXEPRE-SKCDODSBSA-N CC1C(C)=CC(C([C@@H](CC2)[C@@](C)(CC3)[C@@H]2C(CC2)[C@H]3[C@@](C)(CC3)[C@@H]2C[C@]3(C)O)=O)=CC1 Chemical compound CC1C(C)=CC(C([C@@H](CC2)[C@@](C)(CC3)[C@@H]2C(CC2)[C@H]3[C@@](C)(CC3)[C@@H]2C[C@]3(C)O)=O)=CC1 OYCAXWJZOXEPRE-SKCDODSBSA-N 0.000 description 1
- QUECWXYHZYXRNL-AKMKAEOHSA-N CCC(CC1)([C@](C)(CC2)C(C)(CC3)C2C(C2C(C4)C4C(N(C)C)=CC2)=O)[C@@]3(C)C(C)(CC2)[C@H]1C[C@]2(C)O Chemical compound CCC(CC1)([C@](C)(CC2)C(C)(CC3)C2C(C2C(C4)C4C(N(C)C)=CC2)=O)[C@@]3(C)C(C)(CC2)[C@H]1C[C@]2(C)O QUECWXYHZYXRNL-AKMKAEOHSA-N 0.000 description 1
- LBMMGQNKAKKYFQ-INLHBMBJSA-N CCC(CC[C@](C)(C1)[O]=C)(C(C)CC2)[C@@]1(C)CCC[C@H](CC1)[C@@]2(C)C1C(c(cc1)cc(C)c1F)=O Chemical compound CCC(CC[C@](C)(C1)[O]=C)(C(C)CC2)[C@@]1(C)CCC[C@H](CC1)[C@@]2(C)C1C(c(cc1)cc(C)c1F)=O LBMMGQNKAKKYFQ-INLHBMBJSA-N 0.000 description 1
- PSLHTBSZNHOGDF-JYQNWREZSA-N C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1ccc(C)cc1)=N Chemical compound C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1ccc(C)cc1)=N PSLHTBSZNHOGDF-JYQNWREZSA-N 0.000 description 1
- SHQUFCQNCSMJHQ-LAWOIKPDSA-N C[C@@H](CCC1(C)[C@@H]2C(CC3)CCC[C@H](C(c4ccc(C)c(F)c4)O)C(C)CC2)C[C@@]13N Chemical compound C[C@@H](CCC1(C)[C@@H]2C(CC3)CCC[C@H](C(c4ccc(C)c(F)c4)O)C(C)CC2)C[C@@]13N SHQUFCQNCSMJHQ-LAWOIKPDSA-N 0.000 description 1
- NJZLRUALCFJKFJ-SUSYSVFISA-N C[C@@](CC[C@@H](C1CC2)C(CC[C@](C)(C3)O)C23N)(C(CC2)C(c3ccccc3I)=C)[C@]12N Chemical compound C[C@@](CC[C@@H](C1CC2)C(CC[C@](C)(C3)O)C23N)(C(CC2)C(c3ccccc3I)=C)[C@]12N NJZLRUALCFJKFJ-SUSYSVFISA-N 0.000 description 1
- JDJYBSSMKXYWBA-ROEXDCMRSA-N C[C@H](CC1)[C@](C)(CC[C@@H](CCC2)[C@@H](CC3)[C@@H]2C[C@]3(C)O)[C@H]1C(c(cc1)ccc1OC)=O Chemical compound C[C@H](CC1)[C@](C)(CC[C@@H](CCC2)[C@@H](CC3)[C@@H]2C[C@]3(C)O)[C@H]1C(c(cc1)ccc1OC)=O JDJYBSSMKXYWBA-ROEXDCMRSA-N 0.000 description 1
- BOBXFKPVTXBFDX-XKKDOOBNSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H]1[C@H]3CC(C)(C)CC1)[C@H]2C(c1cnc[nH]1)=[U] Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H]1[C@H]3CC(C)(C)CC1)[C@H]2C(c1cnc[nH]1)=[U] BOBXFKPVTXBFDX-XKKDOOBNSA-N 0.000 description 1
- YDUKUYRDNOIQBA-LSBZSBGNSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1Cl)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1Cl)=O YDUKUYRDNOIQBA-LSBZSBGNSA-N 0.000 description 1
- UXTNTNONGLSRPS-RGYBDQPCSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cc1)cc(cc2)c1cc2OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cc1)cc(cc2)c1cc2OC)=O UXTNTNONGLSRPS-RGYBDQPCSA-N 0.000 description 1
- IOSGZVVLXFCLDP-SCNDPVEVSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cccc([I]=C)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cccc([I]=C)c1)=O IOSGZVVLXFCLDP-SCNDPVEVSA-N 0.000 description 1
- LEOLRQXBZFHWNP-XIGAYJBWSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC[C@](C)(C1)O)[C@]31N)[C@H]2C(c1ccc(C)cc1)=C Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC[C@](C)(C1)O)[C@]31N)[C@H]2C(c1ccc(C)cc1)=C LEOLRQXBZFHWNP-XIGAYJBWSA-N 0.000 description 1
- SIUDUIXAPIRZAZ-BFNNADBGSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC[C@](C)(C1)[N+]([O-])=O)[C@]31N)[C@H]2C(c1c(C)cccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC[C@](C)(C1)[N+]([O-])=O)[C@]31N)[C@H]2C(c1c(C)cccc1)=O SIUDUIXAPIRZAZ-BFNNADBGSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
- GRXKLBBBQUKJJZ-UHFFFAOYSA-N Soman Chemical compound CC(C)(C)C(C)OP(C)(F)=O GRXKLBBBQUKJJZ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- PJVJTCIRVMBVIA-JTQLQIEISA-N [dimethylamino(ethoxy)phosphoryl]formonitrile Chemical compound CCO[P@@](=O)(C#N)N(C)C PJVJTCIRVMBVIA-JTQLQIEISA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 description 1
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021090965A JP7186259B2 (ja) | 2014-11-27 | 2021-05-31 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2022189056A JP2023022187A (ja) | 2014-11-27 | 2022-11-28 | Ｃｎｓ障害を処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014092369 | 2014-11-27 | ||
| CNPCT/CN2014/092369 | 2014-11-27 | ||
| PCT/CN2015/095765 WO2016082789A1 (en) | 2014-11-27 | 2015-11-27 | Compositions and methods for treating cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021090965A Division JP7186259B2 (ja) | 2014-11-27 | 2021-05-31 | Ｃｎｓ障害を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535586A JP2017535586A (ja) | 2017-11-30 |
| JP2017535586A5 true JP2017535586A5 (enExample) | 2019-01-10 |
| JP6893173B2 JP6893173B2 (ja) | 2021-06-23 |
Family
ID=56073637
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528154A Active JP6893173B2 (ja) | 2014-11-27 | 2015-11-27 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2021090965A Active JP7186259B2 (ja) | 2014-11-27 | 2021-05-31 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2022189056A Pending JP2023022187A (ja) | 2014-11-27 | 2022-11-28 | Ｃｎｓ障害を処置するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021090965A Active JP7186259B2 (ja) | 2014-11-27 | 2021-05-31 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2022189056A Pending JP2023022187A (ja) | 2014-11-27 | 2022-11-28 | Ｃｎｓ障害を処置するための組成物および方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10774108B2 (enExample) |
| EP (2) | EP3224269B1 (enExample) |
| JP (3) | JP6893173B2 (enExample) |
| CY (1) | CY1123200T1 (enExample) |
| DK (1) | DK3224269T3 (enExample) |
| ES (1) | ES2793237T3 (enExample) |
| HR (1) | HRP20200840T1 (enExample) |
| HU (1) | HUE049014T2 (enExample) |
| LT (1) | LT3224269T (enExample) |
| ME (1) | ME03749B (enExample) |
| PL (1) | PL3224269T3 (enExample) |
| PT (1) | PT3224269T (enExample) |
| RS (1) | RS60343B1 (enExample) |
| SI (1) | SI3224269T1 (enExample) |
| SM (1) | SMT202000276T1 (enExample) |
| WO (1) | WO2016082789A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| HRP20200995T1 (hr) | 2013-04-17 | 2020-11-27 | Sage Therapeutics, Inc. | 19-nor neuroaktivni steroidi za metode liječenja |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| HRP20190232T1 (hr) | 2013-04-17 | 2019-03-22 | Sage Therapeutics, Inc. | 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu |
| SMT202100229T1 (it) | 2013-07-19 | 2021-05-07 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| SMT202100048T1 (it) | 2013-08-23 | 2021-03-15 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| JP6742308B2 (ja) | 2014-10-16 | 2020-08-19 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
| AU2015331749A1 (en) | 2014-10-16 | 2017-05-04 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| ES2793237T3 (es) | 2014-11-27 | 2020-11-13 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| SI3250210T1 (sl) | 2015-01-26 | 2021-07-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20200306262A1 (en) * | 2015-11-20 | 2020-10-01 | Sage Therapeutics, Inc. | Compounds and methods of their use |
| US10435396B2 (en) * | 2016-03-03 | 2019-10-08 | Bayer Pharma Aktiegesellschaft | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
| AU2017296295B2 (en) * | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| CN109689673B (zh) * | 2016-07-11 | 2023-03-14 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
| CN115974954A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| MA51315A (fr) * | 2017-12-22 | 2020-10-28 | Sage Therapeutics Inc | Compositions et méthodes permettant de traiter des troubles du snc |
| MA53660A (fr) * | 2018-09-19 | 2021-07-28 | Modernatx Inc | Analogues de stérol et leurs utilisations |
| CN109369762B (zh) * | 2018-10-31 | 2021-06-18 | 湖南玉新药业有限公司 | 17-甲酸甾族化合物的制备方法 |
| CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| US20230346801A1 (en) | 2020-03-25 | 2023-11-02 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| US12208103B1 (en) | 2021-05-07 | 2025-01-28 | Lipocine Inc. | Compositions and methods for treating CNS disorders |
| US11337987B1 (en) | 2021-05-07 | 2022-05-24 | Lipocine Inc. | Compositions and methods for treating central nervous system disorders |
Family Cites Families (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| FR1380417A (fr) | 1962-05-15 | 1964-12-04 | Roussel Uclaf | Nouveaux androstanyl-pyrazoles et procédé de préparation |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| GB1434919A (en) | 1972-06-15 | 1976-05-12 | Glaxo Lab Ltd | 3alpha-hydroxy androstanes |
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| GB1380246A (en) * | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1436324A (en) * | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
| DK134348C (da) | 1973-11-30 | 1977-03-21 | Schering Ag | Analogifremgangsmade til fremstilling af d-homo-20-ketopregnaner |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2438020A1 (de) | 1974-08-05 | 1976-02-26 | Schering Ag | 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1581234A (en) * | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0603312A4 (en) | 1991-09-13 | 1995-06-07 | Cocensys Inc | NEW GABA A RECEPTOR WITH STEROID BINDING POINTS. |
| DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| NZ282939A (en) | 1994-02-14 | 1998-08-26 | Cocensys Inc | Androstanes and pregnanes for allosteric modulation of gaba receptors |
| AU3125695A (en) | 1994-07-21 | 1996-02-22 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
| WO1996016076A1 (en) | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| KR19990022323A (ko) | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
| CA2321728C (en) | 1998-03-11 | 2008-12-09 | Torbjorn Backstrom | Epiallopregnanolone in the treatment of cns disorders |
| CN1187367C (zh) | 1999-04-29 | 2005-02-02 | 欧洲凯尔特股份有限公司 | 具有麻醉剂活性的3α－羟基－3β－甲氧基甲基－21－杂环取代的类固醇 |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| EP1172371B1 (en) | 2000-02-18 | 2005-06-08 | Taiho Pharmaceutical Company Limited | Process for the preparation of steroid derivatives |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| WO2002036605A2 (en) | 2000-11-03 | 2002-05-10 | Washington University | Estrone-derivatives having cytoprotective activity |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| EA011123B1 (ru) | 2003-03-24 | 2008-12-30 | Стерикс Лимитед | Производные эстрогена в качестве ингибиторов стероидной сульфатазы |
| US7781421B2 (en) | 2003-05-29 | 2010-08-24 | Washington University | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods |
| JP2007512344A (ja) | 2003-11-24 | 2007-05-17 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体調節剤 |
| US20090118248A1 (en) | 2004-04-23 | 2009-05-07 | Euro-Celtique S.A. | 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| WO2006110172A2 (en) | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals.Inc. | Steroid analogs and characterization and treatment methods |
| PT2168585E (pt) | 2005-06-09 | 2012-03-05 | Euro Celtique Sa | Composições farmacêuticas de um esteróide neuroactivo e as suas utilizações |
| ES2607852T3 (es) | 2006-11-21 | 2017-04-04 | Umecrine Ab | El uso de esteroides de pregnano y androstano para la fabricación de una composición farmacéutica para el tratamiento de trastornos del SNC |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| AU2008265898B2 (en) | 2007-06-15 | 2013-11-28 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CZ2008434A3 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| WO2010054158A2 (en) | 2008-11-07 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| EP2598513A1 (en) | 2010-07-30 | 2013-06-05 | Medexis S.A. | Compounds and methods for treating neoplasia |
| EP2667876A2 (en) | 2010-12-15 | 2013-12-04 | Harbor BioSciences, Inc. | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
| CZ303443B6 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| US9457033B2 (en) | 2011-02-15 | 2016-10-04 | Socpra Sciences Et Genie, S.E.C. | Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| EP2695948B1 (en) | 2011-03-23 | 2016-12-28 | Etsuro Ito | Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| US20150158903A1 (en) | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| WO2013112605A2 (en) | 2012-01-23 | 2013-08-01 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| SG10201607230SA (en) | 2012-06-19 | 2016-10-28 | Intercept Pharmaceuticals Inc | Preparation, Uses And Solid Forms Of Obeticholic Acid |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| ES3056529T3 (en) * | 2012-11-09 | 2026-02-23 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| EP4335505A3 (en) | 2012-11-30 | 2024-06-05 | The Regents of The University of California | Anticonvulsant activity of steroids |
| BR112015014397B1 (pt) | 2012-12-18 | 2021-02-02 | Washington University | composto, composição farmacêutica e uso de um composto |
| US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| CA2831054C (en) | 2013-01-09 | 2016-08-30 | Sapna Life Sciences Corp. | Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury |
| GB201302368D0 (en) | 2013-02-11 | 2013-03-27 | Univ Bath | Compound |
| US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| WO2014169831A1 (en) * | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| HRP20190232T1 (hr) | 2013-04-17 | 2019-03-22 | Sage Therapeutics, Inc. | 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu |
| HRP20200995T1 (hr) | 2013-04-17 | 2020-11-27 | Sage Therapeutics, Inc. | 19-nor neuroaktivni steroidi za metode liječenja |
| SMT202100229T1 (it) | 2013-07-19 | 2021-05-07 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| SMT202100048T1 (it) | 2013-08-23 | 2021-03-15 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| HUE050028T2 (hu) | 2014-05-29 | 2021-12-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásuk |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3188734A4 (en) | 2014-09-02 | 2018-01-10 | The Texas A&M University System | Method of treating organophosphate intoxication |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| AU2015331749A1 (en) | 2014-10-16 | 2017-05-04 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| JP6742308B2 (ja) | 2014-10-16 | 2020-08-19 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
| ES2793237T3 (es) | 2014-11-27 | 2020-11-13 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| SI3250210T1 (sl) | 2015-01-26 | 2021-07-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016164763A1 (en) | 2015-04-10 | 2016-10-13 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| AR105044A1 (es) | 2015-06-18 | 2017-08-30 | Sage Therapeutics Inc | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| CN108350021A (zh) | 2015-09-08 | 2018-07-31 | 视点医疗公司 | 用于治疗眼科疾病的化合物和制剂 |
| EP3362042A1 (en) | 2015-10-16 | 2018-08-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| US20200306262A1 (en) | 2015-11-20 | 2020-10-01 | Sage Therapeutics, Inc. | Compounds and methods of their use |
| SG11201807785VA (en) | 2016-03-08 | 2018-10-30 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| CN109689673B (zh) | 2016-07-11 | 2023-03-14 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| CN115974954A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| KR102680786B1 (ko) | 2017-08-31 | 2024-07-02 | 다케다 야쿠힌 고교 가부시키가이샤 | Cns 병태의 치료 |
| AU2018327357B2 (en) | 2017-09-07 | 2024-08-22 | Sage Therapeutics, LLC | Neuroactive steroids and their methods of use |
| US20200276209A1 (en) | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| EP4696301A2 (en) | 2017-09-14 | 2026-02-18 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| SG10202110563YA (en) | 2017-11-10 | 2021-11-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| AR114044A1 (es) | 2017-12-22 | 2020-07-15 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central |
| MA51315A (fr) | 2017-12-22 | 2020-10-28 | Sage Therapeutics Inc | Compositions et méthodes permettant de traiter des troubles du snc |
| JP7538040B2 (ja) | 2018-01-12 | 2024-08-21 | セージ セラピューティクス， インコーポレイテッド | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
| AU2019287491B2 (en) | 2018-06-12 | 2025-05-15 | Sage Therapeutics, LLC | A 19-nor C3,3-disubstituted C21 -N-pyrazolyl steroid and methods of use thereof |
| EP3864022B1 (en) | 2018-10-12 | 2023-09-20 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
| AU2019359899B2 (en) | 2018-10-19 | 2024-07-04 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| BR112021010996A2 (pt) | 2018-12-05 | 2021-08-31 | Sage Therapeutics, Inc. | Esteroides neuroativos e seus métodos de uso |
| WO2020132504A1 (en) | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| CN114729000A (zh) | 2019-06-27 | 2022-07-08 | 萨奇治疗股份有限公司 | 用于治疗cns病症的化合物 |
| CN114787174A (zh) | 2019-06-27 | 2022-07-22 | 萨奇治疗股份有限公司 | 用于治疗cns病症的组合物和方法 |
| AU2020302748A1 (en) | 2019-06-27 | 2022-01-06 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| CN114761019A (zh) | 2019-12-05 | 2022-07-15 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| TW202143976A (zh) | 2020-03-18 | 2021-12-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| US20230346801A1 (en) | 2020-03-25 | 2023-11-02 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| EP4172171A1 (en) | 2020-06-24 | 2023-05-03 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
| PE20231301A1 (es) | 2020-07-20 | 2023-08-24 | Sage Therapeutics Inc | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso de este |
| MX2023006063A (es) | 2020-11-25 | 2023-08-09 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central. |
| JP2024507638A (ja) | 2021-01-28 | 2024-02-21 | セージ セラピューティクス， インコーポレイテッド | 性機能障害処置のための神経刺激性ステロイドの使用 |
| US20240148756A1 (en) | 2021-02-18 | 2024-05-09 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| WO2022197901A1 (en) | 2021-03-17 | 2022-09-22 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| JP2024513581A (ja) | 2021-04-12 | 2024-03-26 | セージ セラピューティクス， インコーポレイテッド | 本態性振戦の治療 |
| AU2022267304A1 (en) | 2021-04-29 | 2023-11-02 | Sage Therapeutics, LLC | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| KR20240006026A (ko) | 2021-04-29 | 2024-01-12 | 세이지 테라퓨틱스, 인크. | 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
-
2015
- 2015-11-27 ES ES15862506T patent/ES2793237T3/es active Active
- 2015-11-27 EP EP15862506.1A patent/EP3224269B1/en active Active
- 2015-11-27 SM SM20200276T patent/SMT202000276T1/it unknown
- 2015-11-27 PL PL15862506T patent/PL3224269T3/pl unknown
- 2015-11-27 PT PT158625061T patent/PT3224269T/pt unknown
- 2015-11-27 HR HRP20200840TT patent/HRP20200840T1/hr unknown
- 2015-11-27 JP JP2017528154A patent/JP6893173B2/ja active Active
- 2015-11-27 EP EP20159317.5A patent/EP3719029A1/en not_active Ceased
- 2015-11-27 LT LTEP15862506.1T patent/LT3224269T/lt unknown
- 2015-11-27 WO PCT/CN2015/095765 patent/WO2016082789A1/en not_active Ceased
- 2015-11-27 US US15/531,313 patent/US10774108B2/en active Active
- 2015-11-27 DK DK15862506.1T patent/DK3224269T3/da active
- 2015-11-27 RS RS20200610A patent/RS60343B1/sr unknown
- 2015-11-27 HU HUE15862506A patent/HUE049014T2/hu unknown
- 2015-11-27 SI SI201531219T patent/SI3224269T1/sl unknown
- 2015-11-27 ME MEP-2020-105A patent/ME03749B/me unknown
-
2020
- 2020-02-25 US US16/800,053 patent/US20210017218A1/en not_active Abandoned
- 2020-05-26 CY CY20201100480T patent/CY1123200T1/el unknown
-
2021
- 2021-05-31 JP JP2021090965A patent/JP7186259B2/ja active Active
-
2022
- 2022-10-04 US US17/959,592 patent/US11945836B2/en active Active
- 2022-11-28 JP JP2022189056A patent/JP2023022187A/ja active Pending
-
2024
- 2024-02-20 US US18/581,595 patent/US20250042934A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535586A5 (enExample) | ||
| JP2018502891A5 (enExample) | ||
| CA2904794C (en) | Modulators of the eif2alpha pathway | |
| JP2016525121A5 (enExample) | ||
| RU2017116732A (ru) | Композиции и способы для лечения расстройств цнс | |
| JP2016531134A5 (enExample) | ||
| RU2016105436A (ru) | Нейроактивные стероиды, композиции и их использование | |
| JP2020514318A5 (enExample) | ||
| ME03809B (me) | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a | |
| EA200500164A1 (ru) | N-арилдиазаспирациклические соединения и способы их получения и применения | |
| MY147442A (en) | Imidazoquinolines as lipid kinase inhibitors | |
| JP2015512951A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| RU2015143841A (ru) | Ингибиторы hdac | |
| JP2020535165A5 (enExample) | ||
| MA32108B1 (fr) | Derives d'indazole | |
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| MA46342B1 (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| JP2012514006A5 (enExample) | ||
| JP2005514370A5 (enExample) | ||
| FI3541784T3 (fi) | Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina | |
| EA201070898A1 (ru) | Новое производное хиназолин-2,4-диона и лекарственные композиции на его основе для профилактики и лечения заболевания, обусловленного поражением черепно-мозгового нерва | |
| PE20140999A1 (es) | Inhibidores de catepsina c. | |
| EA200702199A1 (ru) | Новые соединения для лечения воспалительных заболеваний | |
| MX2023000437A (es) | Derivado de bencisoxazol. |